SALT LAKE CITY, November 28, 2021 / PRNewswire / – Novarad, a leading provider of medical software, announced today that it has expanded its strategic partnership with mammography analysis company, PenRad, Inc. The automated tracking and PenRad report for lung screening, PenLung will integrate into Novarad’s NovaPACS with imaging companies.
The NovaPACS platform is focused on improving patient health and efficient management of workflows by providing a simple yet elegant solution for reading and reporting. The fully integrated platform and its multiple components allow users to view many types of studies from a single workstation.
In addition to the PenConnect and PenTrac products, Novarad will offer PenLung, a lung nodule monitoring and reporting platform, as well as PenAlert. PenLung and PenAlert are automated solutions for reporting CT lung screening results for nearly 50 distinct anomaly profiles and 30 Lung-RADS combinations for audit and recall requirements. PenLung also makes it easy to upload to the National Lung CT Scan Registry, which is a requirement for every LDCT lung cancer screening performed.
“We are delighted to be able to add PenLung and PenAlert to the arsenal of products that provide radiologists with the tools necessary to provide faster and more accurate diagnoses, resulting in better patient care and reduced patient vulnerability.” , said David Grandpre, Senior Product Manager at Novarad. “Recent changes to LDCT lung screening guidelines and a 37% increase in payments for ambulatory lung imaging will drive demand for more efficient workflow and analysis programs; NovaPACS with PenLung does the trick. “
“PenLung Low Dose CT scanning software provides radiology departments with optimized workflow benefits and follow-up efficiency previously reserved for women’s imaging programs,” said Greg Gustavson, President and CEO of PenRad Technologies, Inc. Gustafson goes on to state that “PenLung’s growth coincides with the expansion of LDCT lung screening programs in the United States and is driven by the release of new screening guidelines by LDCT. the expansion gives us hope that early detection rates will increase in the years to come. “
PenRad and Novarad will participate in the 2021 Radiological Society of North America (RSNA) Annual meeting, scheduled for November 28 – December 2, 2021 in Chicago, Illinois. Visit PenRad at booth # 3117 and Novarad at booth # 1729 to learn more about this new partnership and how it can help you meet current and future healthcare demands.
Novarad empowers healthcare providers to take control of their medical images with its comprehensive diagnostic suite. Ncompass enterprise imaging, along with user-configurable clinical workflow modules, provide facilities with the solutions they need to accelerate quality of care while ensuring consistent and predictable costs. The innovative OpenSight augmented reality system superimposes medical images directly onto the patient’s body to enable accurate recording for surgical planning. Novarad improves the practice of medicine by continuously developing and refining our advanced imaging technologies for the benefit of providers and patients. Visit Novarad at www.novarad.net for more information.
PenRad, a software provider to improve productivity for: breast imaging – PenRad, LDCT lung screening – PenLung, general radiology – PenAlert, genetic analysis – PenGen. PenRad invests in the healthcare community in diagnostic technology, techniques and analysis. PenRad provides software and leadership in standardization. These include the HL7 working groups, the Clinical Interoperability Modeling Initiative (CIMI) and the Cancer-Interoperability project supported by the ONC, FDA, CDC, NCI, NIH and RSNA. For more information, visit the company’s website: www.penrad.com.
SOURCE Novarad Corporation